Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 6Gynecologic 6Lymphoid 5Breast 5Other solid neoplasm 3CNS 3Tumor-Agnostic 2Thoracic 2Plasma cell 2Genitourinary 2Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ridaforolimus × Thoracic × Clear all
NCT01212627 2021-02-16

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Brown University

Phase 1 Terminated
12 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00818675 2015-01-21

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Merck Sharp & Dohme LLC

Phase 2 Terminated
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡